gip and glp 1 The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 & GIP Agonists |

Beyond their hypoglycemic and metabolic effects, GLP-1based therapies have demonstrated anti-inflammatory effects, with in vitro and in vivo accumulating evidence demonstrating that GLP-1 reduces levels of inflammatory markers [[30], [31], [32]]

doi: 10.2337/dc16-0691 [DOI] [PubMed] [Google Scholar] 58

GLP-1-based treatments mark a major advancement in managing obesity and type 2 diabetes, offering added benefits for heart and brain health

The anti-obesity medication (AOM) marketplace is rapidly expanding, with analysts estimating it to be worth $150 billion by 2032, fueled by the increasing demand for effective weight management (e.g., 15-25% weight loss) and metabolic health solutions

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list for outsourcing facilities, finding no clinical need for large-scale compounding of those substances

You might feel: Sadness or depression Anxiety about trying again Guilt or self-blame Fear of another miscarriage Anger or frustration These feelings are normal and valid